HS
DFTX

Horan Securities’s Definium Therapeutics DFTX Stock Holding History

Horan Securities’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2
Closed -$7 – 437
2023
Q2 		$7 Hold
2
– – ﹤0.01% 718
2023
Q1 		$6 Sell
2
-33
-94% -$110 ﹤0.01% 737
2022
Q4 		$77 Hold
35
– – ﹤0.01% 773
2022
Q3 		$0 Buy
35
+33
+1,650% +$317 ﹤0.01% 721
2022
Q2 		$0 Buy
+2
New +$25 ﹤0.01% 721

Other funds holding DFTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Horan Securities's DFTX Position: Q3 2023 in Review

Horan Securities sold out of Definium Therapeutics (DFTX) in Q3 2023, closing a stake of 2 shares — an estimated $7 sold.

Horan Securities first reported a position in DFTX in Q2 2022 and held it in 5 quarters. The position peaked at $77 in Q4 2022. 93 funds tracked by Wall St. Rank hold DFTX as of Q3 2023.

  • Horan Securities reported no remaining Definium Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Horan Securities sold 2 Definium Therapeutics shares in Q3 2023, an estimated $7.
  • Horan Securities first reported a position in Definium Therapeutics in Q2 2022 and held it in 5 quarters.
  • Horan Securities's Definium Therapeutics position peaked at $77 in Q4 2022.
  • 93 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2023.

Based on Horan Securities's 13F filing for Q3 2023, filed 1 Nov 2023.